nach oben

14.05.2024 | Case Report

Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

verfasst von: Makiko Urabe, Kenji Ikezawa, Kazuhiro Kozumi, Yugo Kai, Ryoji Takada, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Hirofumi Akita, Kazuyoshi Ohkawa

Erschienen in: Clinical Journal of Gastroenterology

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according to pancreatic ductal adenocarcinoma (PDAC). Herein, we describe a recurrent PACC case of an older adult patient. The patient was treated with systemic chemotherapy, chemoradiotherapy, and maintenance therapy based on the pathologic germline BRCA2 variant, resulting in long-term survival. The pathogenic BRCA variant is detected more frequently in patients with PACC than in those with PDAC. The BRCA variant significantly impacts treatment selection and prognosis; therefore, early genomic analysis is recommended when treating PACC.

Satake T, Morizane C, Rikitake R, et al. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57:890–901.CrossRefPubMedPubMedCentral

Ikezawa K, Urabe M, Kai Y, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol. 2024;54:271–81.CrossRefPubMed

Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.CrossRefPubMed

Huang X, Li M, Zhang L, et al. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: a single institutional comparison to pancreatic ductal adenocarcinoma. Surg Oncol. 2021;37: 101528.CrossRefPubMed

Petrova E, Wellner J, Nording AK, et al. Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the German Cancer registry group. Cancers (Basel). 2021;13:6121.CrossRefPubMed

Bellotti R, Paiella S, Primavesi F, et al. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas—a multicentric European study on radically resected patients. HPB (Oxford). 2023;25:1411–9.CrossRefPubMed

Shin SH, Hwang HK, Jang JY, et al. Clinical characteristics of resected acinar cell carcinoma of the pancreas: a Korean multi-institutional study. Cancers (Basel). 2021;13:5095.CrossRefPubMed

Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77–82.CrossRefPubMed

Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature. Clin Med Insights Oncol. 2022;16:11795549221090186.CrossRefPubMedPubMedCentral

10.

Stossel C, Raitses-Gurevich M, Atias D, et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 2023;13:1826–43.CrossRefPubMedPubMedCentral

11.

Florou V, Elliott A, Bailey MH, et al. Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC. Clin Cancer Res. 2023;29:3408–17.CrossRefPubMed

12.

Sakakida T, Ishikawa T, Doi T, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575–85.CrossRefPubMedPubMedCentral

13.

Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929–39.CrossRefPubMedPubMedCentral

14.

Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.CrossRefPubMedPubMedCentral

15.

Sakakida T, Ishikawa T, Doi T, et al. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database. J Gastroenterol. 2023;59:145–56.CrossRefPubMed

16.

Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.CrossRefPubMedPubMedCentral

17.

Yamai T, Ikezawa K, Sugimoto N, et al. Utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice. Cancers (Basel). 2023;15:970.CrossRefPubMed

18.

Takahashi K, Takeda Y, Ono Y, et al. Current status of molecular diagnostic approaches using liquid biopsy. J Gastroenterol. 2023;58:834–47.CrossRefPubMedPubMedCentral

19.

Skorupan N, Ghabra S, Maldonado JA, et al. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? J Cancer Metastasis Treat. 2023;9:5.PubMedPubMedCentral

20.

Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol. 2023;41:5151–62.CrossRefPubMed

21.

Nakayama S, Fukuda A, Kou T, et al. A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy. Clin J Gastroenterol. 2023;16:610–4.CrossRefPubMed

22.

Izumo W, Higuchi R, Furukawa T, et al. A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis. Clin J Gastroenterol. 2022;15:642–8.CrossRefPubMed

23.

Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28:493–511.CrossRefPubMedPubMedCentral

24.

Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma. version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439–57.CrossRefPubMed

25.

Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.CrossRefPubMedPubMedCentral

26.

Kim KH, Kim HS, Kim SS, et al. Increased radiosensitivity of solid tumors harboring ATM and BRCA1/2 mutations. Cancer Res Treat. 2022;54:54–64.CrossRefPubMed

27.

Price JM, Prabhakaran A, West CML. Predicting tumor radiosensitivity to deliver precision radiotherapy. Nat Rev Clin Oncol. 2023;20:83–98.CrossRefPubMed

Titel: Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma
verfasst von: Makiko Urabe
Kenji Ikezawa
Kazuhiro Kozumi
Yugo Kai
Ryoji Takada
Kaori Mukai
Tasuku Nakabori
Hiroyuki Uehara
Hirofumi Akita
Kazuyoshi Ohkawa
Publikationsdatum: 14.05.2024
Verlag: Springer Nature Singapore
Erschienen in: Clinical Journal of Gastroenterology
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-024-01981-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin